Aditxt (NASDAQ:ADTX – Get Free Report) and Evolus (NASDAQ:EOLS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.
Profitability
This table compares Aditxt and Evolus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
| Evolus | -10.85% | N/A | -13.00% |
Valuation and Earnings
This table compares Aditxt and Evolus”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $14,336.00 | 0.05 | -$41.71 million | ($100,788.35) | -0.00 |
| Evolus | $297.18 million | 1.64 | -$51.64 million | ($0.52) | -14.18 |
Aditxt has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Aditxt and Evolus, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
Evolus has a consensus price target of $14.50, indicating a potential upside of 96.64%. Given Evolus’ stronger consensus rating and higher probable upside, analysts plainly believe Evolus is more favorable than Aditxt.
Volatility and Risk
Aditxt has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
Insider and Institutional Ownership
15.5% of Aditxt shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 5.0% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Evolus beats Aditxt on 11 of the 14 factors compared between the two stocks.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
